Pediatric Tumors research
Tumors are an important cause of illness and death in children. In Spain, 1,500 new cases of childhood cancer are registered each year.
Los Tumors of the central nervous system are the most frequent malignant solid tumors in children. On the other hand, childhood bone tumors (osteosarcomas) are a group of high-grade tumors with great heterogeneity and the capacity to develop metastasis.
These two tumor types lead the causes of childhood cancer mortality. This is because, despite treatment with surgery, radio and/or polychemotherapy, the overall survival associated with these types of tumors has not improved substantially in recent years.
Need more information?
If you are interested in learning more about our research, please contact us.
We dream of curing pediatric tumors.
Although cancer therapy has advanced significantly in recent years, much remains to be discovered in the case of childhood cancer. Our goal is to improve the quality of life and survival of children with cancer.
To deepen the knowledge of the underlying biology of these childhood tumors, the mechanisms involved in their development and the tumor microenvironment.
We seek to find new biomarkers of the disease and to develop new specific biological therapeutic strategies targeting these tumors.
We work closely with researchers and clinicians to rapidly translate findings from the laboratory to the patient.
How do we investigate paediatric tumours?
Cima's research on paediatric tumours is part of the Neuro-oncology, Sarcomas, and Paediatric Tumours Research Area of the Clínica Universidad de Navarra Cancer Centre.
Our tumores pediátricos research group
REFERENCES IN TRANSLATIONAL RESEARCH
Advanced Therapies for Paediatric Solid Tumours Research Group
The Advanced Therapies for Paediatric Solid Tumours group is focused on the development of new therapeutic tools based, preferentially, on oncolytic viruses.
To evaluate these therapies we have relevant preclinical models, always with the patient in mind.
It is part of the Solid Tumors Program.